share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股SEC公告 ·  09/27 16:05
Moomoo AI 已提取核心信息
TransCode Therapeutics, Inc. is facing potential delisting from The Nasdaq Capital Market due to non-compliance with several listing requirements. The company, incorporated in Delaware and trading under the symbol RNAZ, received a Minimum Bid Price Deficiency Letter from Nasdaq on August 13, 2024, indicating that its stock had not met the minimum closing bid price of $1.00 per share for 30 consecutive business days. Additionally, TransCode received a Stockholders' Equity Requirement Deficiency Letter for failing to maintain the minimum stockholders' equity of $2.5 million. A subsequent Shareholder Approval Deficiency Letter was issued on September 23, 2024, due to the company's issuance of shares at a significant discount without obtaining shareholder approval, which is required for transactions involving the issuance of 20% or more of the pre-transaction shares outstanding. The company has appealed the delisting determination and a hearing with the Nasdaq Hearings Panel is scheduled for October 1, 2024. The outcome of the hearing will determine whether TransCode can regain compliance and maintain its listing on The Nasdaq Capital Market.
TransCode Therapeutics, Inc. is facing potential delisting from The Nasdaq Capital Market due to non-compliance with several listing requirements. The company, incorporated in Delaware and trading under the symbol RNAZ, received a Minimum Bid Price Deficiency Letter from Nasdaq on August 13, 2024, indicating that its stock had not met the minimum closing bid price of $1.00 per share for 30 consecutive business days. Additionally, TransCode received a Stockholders' Equity Requirement Deficiency Letter for failing to maintain the minimum stockholders' equity of $2.5 million. A subsequent Shareholder Approval Deficiency Letter was issued on September 23, 2024, due to the company's issuance of shares at a significant discount without obtaining shareholder approval, which is required for transactions involving the issuance of 20% or more of the pre-transaction shares outstanding. The company has appealed the delisting determination and a hearing with the Nasdaq Hearings Panel is scheduled for October 1, 2024. The outcome of the hearing will determine whether TransCode can regain compliance and maintain its listing on The Nasdaq Capital Market.
TransCode Therapeutics, Inc.因未能满足多项上市要求，面临着从纳斯达克资本市场摘牌的潜在风险。这家公司在特拉华州注册，并在代号RNAZ下交易，于2024年8月13日收到了纳斯达克发出的最低买盘价不足通知书，显示其股票未连续30个营业日达到每股1.00美元的最低收盘买盘价。此外，TransCode还收到了警示股东权益不达标通知书，因未能保持至少250万美元的最低股东权益。随后，因公司以显着折扣发行股份而未经股东批准，违反了涉及发行20%或更多交易前股份的要求，TransCode还收到了股东批准不足通知书，该批准对交易是必要的。公司已对摘牌决定提出上诉，并与纳斯达克听证会小组定于2024年10月1日进行听证。听证结果将决定TransCode是否可以恢复符合条件，并保持在纳斯达克资本市场的上市地位。
TransCode Therapeutics, Inc.因未能满足多项上市要求，面临着从纳斯达克资本市场摘牌的潜在风险。这家公司在特拉华州注册，并在代号RNAZ下交易，于2024年8月13日收到了纳斯达克发出的最低买盘价不足通知书，显示其股票未连续30个营业日达到每股1.00美元的最低收盘买盘价。此外，TransCode还收到了警示股东权益不达标通知书，因未能保持至少250万美元的最低股东权益。随后，因公司以显着折扣发行股份而未经股东批准，违反了涉及发行20%或更多交易前股份的要求，TransCode还收到了股东批准不足通知书，该批准对交易是必要的。公司已对摘牌决定提出上诉，并与纳斯达克听证会小组定于2024年10月1日进行听证。听证结果将决定TransCode是否可以恢复符合条件，并保持在纳斯达克资本市场的上市地位。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息